1. Patients must have a diagnosis CLL/SLL or Prolymphocytic Leukemia (PLL) and be previously treated. Given the poor outcome of CLL/SLL/PLL patients with 17p del or TP53 mutation to standard frontline chemo-immunotherapy, such patients will be eligible if they are untreated.